Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Cash & Equivalents (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Cash & Equivalents readings, the most recent being $3.8 million for Q3 2025.

  • Quarterly Cash & Equivalents fell 34.61% to $3.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Sep 2025, down 34.61% year-over-year, with the annual reading at $4.1 million for FY2024, 41.45% down from the prior year.
  • Cash & Equivalents hit $3.8 million in Q3 2025 for Greenwich LifeSciences, up from $3.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $30.4 million in Q1 2021 and bottomed at $2.7 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $13.4 million, with a median of $10.9 million recorded in 2023.
  • The largest annual shift saw Cash & Equivalents surged 365.15% in 2021 before it tumbled 56.75% in 2025.
  • Greenwich LifeSciences' Cash & Equivalents stood at $27.2 million in 2021, then plummeted by 50.49% to $13.5 million in 2022, then tumbled by 48.1% to $7.0 million in 2023, then plummeted by 41.45% to $4.1 million in 2024, then fell by 6.97% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Cash & Equivalents are $3.8 million (Q3 2025), $3.1 million (Q2 2025), and $2.7 million (Q1 2025).